生物技术、药物开发和药物输送系统中的纳米颗粒

生物技术、药物开发和药物输送系统中纳米粒子的全球市场规模预计将从 2023 年的 1027 亿美元增长，2023 年至 2028 年的预测期内復合年增长率为 8.8%，达到 2028 年。 2018年增长至1568亿美元。

预计到 2028 年，给药系统行业将从 2023 年的 538 亿美元增长到 751 亿美元，复合年增长率为 6.9%。 诊断行业预计将从 2023 年的 24 亿美元增长到 2028 年的 42 亿美元，复合年增长率为 11.8%。

本报告探讨了生物技术、药物开发和药物输送系统中纳米颗粒的全球市场，提供了市场和产品概述、市场影响因素和市场机会分析、监管环境和市场规模趋势。□预测、详细分析按类别/地区、技术/专利趋势、竞争格局、主要公司概况等

内容

第 1 章简介

第 2 章摘要要点

第 3 章市场概述

• 纳米粒子：概述
• 脂质体
• 量子点
• 树枝状聚合物
• 聚合物纳米颗粒
• 纳米粒子的历史：概述
• 纳米粒子在生物技术中的应用
• 药物开发中的纳米颗粒
• 药物输送系统中的纳米颗粒
• 诊断成像中的纳米颗粒
• 纳米颗粒药物输送领域的主要参与者
• 主要纳米粒子和纳米晶药物
• 市场动态
• 促进因素
• 抑制因素
• PESTEL 分析
• 监管状况
• 纳米粒子最新技术

第 4 章纳米技术在 COVID-19 疫苗製造中的作用

• 抗击新型冠状病毒
• COVID-19 的结构和传染性
• COVID-19 疫苗面临的挑战
• 疫苗设计的组成部分和方法
• 抗原
• 佐剂
• 纳米颗粒和纳米载体
• 设备
• 纳米技术的进步使下一代疫苗成为可能
• 概述：利用纳米技术治疗新冠肺炎 (COVID-19)

第 5 章全球生物技术、药物开发和药物输送系统中的纳米颗粒市场：按技术分类

• 技术概述
• 脂质体
• 聚合物胶束
• 树枝状聚合物
• 其他

第 6 章生物技术、药物开发和药物输送系统领域的全球纳米颗粒市场：按应用分类

• 生物技术
• 药物开发和配方
• 药物输送系统
• 影像诊断

第 7 章纳米颗粒结构

• 纳米颗粒在应用市场中的采用
• 液晶显示屏
• 液体载体
• 脂质体
• 树枝状聚合物
• 壳聚醣海藻酸盐
• 纳米晶体
• 量子点
• 纳米粒子在药物递送中的应用

第 8 章纳米粒子製造

• 纳米颗粒形成方法
• 自组织
• 稳定
• 引入药物的方法
• 聚合物纳米粒子
• 胶束
• 脂质体
• 金和硅纳米颗粒
• 树枝状聚合物
• 如何将生物分子负载到纳米颗粒上
• 纳米药物
• 大规模纳米粒子生产的问题

第 9 章生物技术中的纳米粒子

• 研究与开发
• 干细胞研究
• 细胞修復
• 顺磁性和超顺磁性纳米粒子
• 生物传感器和量子点
• 纳米颗粒研究合作项目

第 10 章药物开发和製剂中的纳米颗粒

• 生物分离
• 快速药物分析
• 去除杂质和毒素
• 使用纳米粒子掺入不溶性药物
• 生物医学中的金银纳米粒子
• 开髮用于 DNA 特异性药物的 DNA 纳米颗粒

第 11 章药物输送系统中的纳米颗粒

• 纳米粒子在药物输送应用中的应用
• 纳米粒子给药系统的设计
• 纳米颗粒药物的稳定性
• 纳米颗粒製剂的尺寸均匀性
• 纳米颗粒的载药量
• 纳米颗粒的药物释放
• 纳米颗粒药物释放的外部触发因素
• 将生物分子偶联并纳入纳米颗粒中
• 纳米颗粒的毒性
• 大规模製造
• 纳米颗粒药物的给药方法
• 口服给药
• 注射给药
• 透皮贴剂
• 种植管理
• 吸入给药
• 适用于药物输送系统的纳米颗粒
• 脂质纳米粒子
• 胶束纳米颗粒
• 树枝状纳米粒子
• 聚合物纳米颗粒
• 金属纳米颗粒
• 生物聚合物纳米颗粒
• 纳米晶体
• 可提供纳米颗粒药物输送系统
• 抗生素纳米颗粒
• 抗肿瘤和通过纳米颗粒递送小分子
• 从纳米颗粒中释放抗癌药物
• 通过纳米粒子传递的生物大分子
• 用于药物输送系统的纳米颗粒涂层
• 从体内去除纳米颗粒

第 12 章体外和体内成像

• 体外成像
• 诊断成像中的纳米颗粒

第 13 章全球生物技术、药物开发和药物输送系统中的纳米颗粒市场：按地区划分

• 市场概览/讨论
• 北美
• 欧洲
• 亚太地区
• 其他地区
• 南美洲
• 中东和非洲

第 14 章竞争格局

• 纳米颗粒药物输送系统和产品
• 纳米颗粒药物输送系统的主要参与者
• 公司纳米颗粒药物输送管道
• 纳米粒子产品和营销：驱动因素
• 纳米粒子产品开发和营销的限制

第 15 章专利、许可、併购

• 近期许可活动/併购
• 最近交易
• 纳米粒子专利

第 16 章公司简介

• BRISTOL-MYERS SQUIBB CO.
• CAMURUS AB
• CERAMISPHERE HEALTH PTY LTD.
• CYTIMMUNE SCIENCES
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• HOFFMANN-LA ROCHE INC.
• MERCK & CO. INC.
• NANOCARRIER CO., LTD.
• NOVARTIS AG

Highlights:

The global nanoparticles in biotechnology, drug development, and drug delivery systems market should reach $156.8 billion by 2028 from $102.7 billion in 2023 at a compound annual growth rate (CAGR) of 8.8% for the forecast period of 2023 to 2028.

Drug delivery systems segment of the global nanoparticles in biotechnology, drug development, and drug delivery systems market is expected to grow from $53.8 billion in 2023 to $75.1 billion in 2028 at a CAGR of 6.9% for the forecast period of 2023 to 2028.

Diagnostics segment of the global nanoparticles in biotechnology, drug development, and drug delivery systems market is expected to grow from $2.4 billion in 2023 to $4.2 billion in 2028 at a CAGR of 11.8% for the forecast period of 2023 to 2028.

Report Scope:

The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development and formulation, drug delivery systems, and diagnostics as well as analyses of global market trends, using 2022 as the base year and forecasting market sizes for 2023 through 2028 with compound annual growth rate (CAGR) projections.

The report includes an analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Market figures are based on revenues at the manufacturer level and are projected in dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded markets for existing products, and other factors affecting the market.

The study is arranged to offer an overview of existing nanoparticle technology and drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic regions and countries. Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.

Figures are reported in U.S. dollars and each case reflects currency fluctuations within the performance of revenue change. Revenue figures do not account for variations in local currencies. All market share data presented is on a global basis unless specifically mentioned.

Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).

Report Includes:

• 25 data tables and 40 additional tables
• An updated overview and in-depth analysis of the global markets for nanoparticles in biotechnology, drug development and drug delivery systems
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for nanoparticles in biotechnology, drug development and drug delivery systems market, and corresponding market share analysis by technology, application and region
• Highlights of the drug development, formulation, and the development of new drug delivery systems and detailed product analyses within health and wellness subsegments
• In-depth information (facts and figures) concerning the major factors influencing the progress of the market (benefits and industry-specific challenges) with respect to specific growth trends, upcoming technologies, prospects, and contributions to the overall market
• Discussion on the role of nanotechnology in the COVID-19 vaccine production, mechanism of action, components and methods in vaccine design for COVID-19 and challenges for vaccine disruptions
• Review of the leading and emerging drug products for each nanoparticle type, clinical trial landscape for various candidate nanodrugs, status of approvals of drugs in each segment, and penetration of technologies and research initiatives within the ecosystem
• Updated information on patents and patent applications on nanoparticles in biotechnology, drug development and drug delivery systems, and related scientific publications
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments, financial performances, and segmental revenues
• Descriptive company profiles of the leading global players in the market, including Bristol-Myers Squibb Co., Camurus, GlaxoSmithKline PLC, Merck & Co. Inc. and Novartis AG

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• What's New in This Report?
• Scope of Report
• Methodology
• Market Estimate
• Information Sources
• Primary Research
• Secondary Research
• Geographic Breakdown
• Market Segmentation
• Analyst's Credentials
• BCC Custom Research
• Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• Introduction to Nanoparticles
• Liposomes
• Quantum Dots
• Dendrimers
• Macromolecule Nanoparticles
• Brief History of Nanoparticles
• Nanoparticles in Biotechnology
• Nanoparticles in Drug Development
• Nanoparticles in Drug Delivery Systems
• Nanoparticles in Diagnostic Imaging
• Major Players in the Nanoparticle Drug Delivery Field
• Major Nanoparticle/Nanocrystal Drugs
• Market Dynamics
• Drivers
• Restraints
• PESTEL Analysis
• Regulatory Landscape
• U.S.
• Europe
• India
• Emerging Technologies in Nanoparticles
• Gadolinium-Neutron Capture Therapy (Gd-NCT) for Glioblastoma Multiforme (GBM) Treatment
• Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to treat Liver Fibrosis

Chapter 4 Role of Nanotechnology in COVID-19 Vaccine Production

• Introduction
• Fight Against Novel Coronavirus
• Structure of COVID-19 and Penetration
• Challenges for COVID-19 Vaccines
• Components and Methods in the Design of Vaccines
• Antigen
• Adjuvant
• Nanoparticle/Nanocarrier
• Device
• Next-Generation Vaccines Enabled Through Advances in Nanotechnology
• Conclusion on Nanotechnology Use Against COVID-19

Chapter 5 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Technology

• Technology Overview
• Liposomes
• Polymeric Micelles
• Dendrimers
• Others

Chapter 6 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Application

• Biotechnology
• Drug Development and Formulation
• Drug Delivery Systems
• Diagnostic Imaging

Chapter 7 Structure of Nanoparticles

• Adoption of Nanoparticles in Applied Markets
• Liquid Crystals
• Liquid Carriers
• Liposomes
• Dendrimers
• Chitosan and Alginate
• Nanocrystals
• Quantum Dots
• Application of Nanoparticles to Drugs Delivered

Chapter 8 Production of Nanoparticles

• Methods of Nanoparticle Formation
• Self-Assembly Production
• Methods of Stabilization
• Methods of Drug Introduction
• Polymeric Nanoparticles
• Micelles
• Liposomes
• Gold and Silicon Nanoparticles
• Dendrimers
• Methods for Loading Biological Molecules into Nanoparticles
• Nanocrystal Drugs
• Problems with Large-Scale Nanoparticle Production

Chapter 9 Nanoparticles in Biotechnology

• Research and Development
• Stem Cell Research
• Cellular Repair
• Paramagnetic and Superparamagnetic Nanoparticles
• Biosensors and Quantum Dots
• Nanoparticle Research Collaborative Programs

Chapter 10 Nanoparticles in Drug Development and Formulation

• Bio Separations
• Rapid Drug Analysis
• Removal of Impurities and Toxins
• Using Nanoparticles to Incorporate Insoluble Drugs
• Gold and Silver Nanoparticles in Biomedicine
• DNA Nanoparticle Development of DNA-Specific Drugs

Chapter 11 Nanoparticles in Drug Delivery Systems

• Nanoparticles in Drug Delivery Applications
• Designing a Nanoparticle Drug Delivery System
• Nanoparticle Drug Stability
• Size Homogeneity of Nanoparticle Preparations
• Drug Loading of Nanoparticles
• Drug Release from Nanoparticles
• External Triggers for Releasing Drugs from Nanoparticles
• Binding/Incorporation of Biomolecules to Nanoparticles
• Nanoparticle Toxicity
• Large-Scale Manufacturing
• Methods of Administration of Nanoparticle Drugs
• Oral Administration
• Injection Administration
• Transdermal Patch
• Implantation Administration
• Inhalation Administration
• Nanoparticles Suitable for Drug Delivery Systems
• Lipid-Based Nanoparticles
• Micelle Nanoparticles
• Dendrimer Nanoparticles
• Polymeric Nanoparticles
• Metal-Based Nanoparticles
• Biological Macromolecule Nanoparticles
• Nanocrystals
• Nanoparticle Drug Delivery Systems Now Available
• Antibiotic Nanoparticles
• Anti-Tumor and Small Molecule Delivery by Nanoparticle
• Release of Anti-Cancer Drugs from Nanoparticles
• Biomacromolecules Delivered by Nanoparticles
• Nanoparticles Coating for Drug Delivery Systems
• Removal of Nanoparticles from the Body

Chapter 12 In Vitro and In Vivo Diagnostic Imaging

• In Vitro Imaging
• Nanoparticles in Diagnostic Imaging

Chapter 13 Global Market for Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems by Region

• Market Overview and Discussion
• North America
• Europe
• Asia-Pacific
• Rest of the World
• South America
• Middle East and Africa

Chapter 14 Competitive Landscape

• Nanoparticle Drug Delivery Systems and Products
• Major Players in Nanoparticle Drug Delivery Systems
• Company Pipelines for Nanoparticle Drug Delivery
• Drivers of Nanoparticle Products and Marketing
• Limiters of Nanoparticle Product Development and Marketing

Chapter 15 Patents, Licensing, Mergers and Acquisitions

• Recent Licensing Activity, Mergers, and Acquisition
• Recent Deals
• Nanoparticle Patents

Chapter 16 Company Profiles

• BRISTOL-MYERS SQUIBB CO.
• CAMURUS AB
• CERAMISPHERE HEALTH PTY LTD.
• CYTIMMUNE SCIENCES
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• HOFFMANN-LA ROCHE INC.
• MERCK & CO. INC.
• NANOCARRIER CO., LTD.
• NOVARTIS AG

List of Tables

• Summary Table A : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, Through 2028
• Summary Table B : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, Through 2028
• Table 1 : Description of Nanoparticles Used in Drug Delivery and Diagnostic Imaging
• Table 2 : Applications of Nanoparticles in Biotechnology
• Table 3 : Applications of Nanoparticles in Drug Development
• Table 4 : Applications of Nanoparticles in Drug Delivery Systems
• Table 5 : Nanoparticles Used in Drug Delivery Systems
• Table 6 : Nanoparticles Used for In Vivo Diagnostic Imaging
• Table 7 : Major Players in the Nanoparticle Drug Field
• Table 8 : Major Nanoparticle/Nanocrystal Drug, by Product and Company
• Table 9 : Description of Nanomaterial Properties and Associated Risks
• Table 10 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, Through 2028
• Table 11 : Global Market for Liposomes Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 12 : Patents Related to Polymeric Micelles and Their Drug Delivery Applications, 2022
• Table 13 : Global Market for Polymeric Micelles Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 14 : Global Market for Dendrimers Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 15 : Global Market for Other Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, Through 2028
• Table 16 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, Through 2028
• Table 17 : Global Market for Nanoparticles in Biotechnology, by Region, Through 2028
• Table 18 : Global Market for Nanoparticles in Drug Development and Formulation, by Region, Through 2028
• Table 19 : Global Market for Nanoparticles in Drug Delivery Systems, by Region, Through 2028
• Table 20 : Global Market for Nanoparticles in Diagnostics, by Region, Through 2028
• Table 21 : Nanoparticles Structure and Properties
• Table 22 : Nanoparticles Systems Approved for Drug Delivery
• Table 23 : Sample of Drugs Delivered Through Liposome Nanotechnology
• Table 24 : Nanoparticles in Biotechnology Applications
• Table 25 : Nano Biosensor Technology Under Development
• Table 26 : ETPN Strategic Research and Innovation Agenda
• Table 27 : Nanoparticles in Drug Development Applications
• Table 28 : Monoclonal antibody (mAb) Drugs with Potential for Use in Nanoparticles Delivery Systems
• Table 29 : Solid Lipid Nanoparticles-Reformatted Drugs
• Table 30 : Nanoparticles in Drug Delivery Applications
• Table 31 : Standard Routes of Drug Administration
• Table 32 : Nanoparticle Transdermal Patch Products
• Table 33 : Type of Nanoparticles Supplied in Drug Delivery Systems
• Table 34 : Mechanism for Removal of Nanoparticles from the Body
• Table 35 : Nanoparticles Contrast Media Used for In Vivo Diagnostic Imaging
• Table 36 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery, by Region, Through 2028
• Table 37 : North American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 38 : European Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 39 : Asia-Pacific Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, Through 2028
• Table 40 : List of Marketed Products Used in Different Nanotechnology-based Techniques
• Table 41 : Major Players in Nanoparticle Drug Development and Formulation Market
• Table 42 : Company Pipeline for Cardiovascular Nanoparticle Drugs
• Table 43 : Company Pipeline for CNS Disease Nanoparticle Drugs
• Table 44 : Company Pipeline for GI Disease Nanoparticle Drugs
• Table 45 : Company Pipeline for Infectious Disease Nanoparticle Drugs
• Table 46 : Company Pipeline for Cancer Nanoparticle Drugs
• Table 47 : Company Pipeline for Ophthalmic Nanoparticle Drugs
• Table 48 : Company Pipeline for Autoimmune Disease Nanoparticle Drugs
• Table 49 : Global Nanotechnology Patents, by Country, 2020-2023
• Table 50 : Bristol-Myers Squibb Co.: Financials, 2020-2022
• Table 51 : Camurus: Financials, 2020-2022
• Table 52 : Camurus: Developments, 2020-2022
• Table 53 : Cytimmune Sciences: Developments, 2020-2022
• Table 54 : Gilead Sciences Inc.: Financials, 2020-2022
• Table 55 : Gilead Sciences Inc.: Developments, 2020-2022
• Table 56 : GlaxoSmithKline PLC: Financials, 2020-2022
• Table 57 : GlaxoSmithKline PLC: Developments, 2020-2022
• Table 58 : Hoffmann-La Roche Inc.: Financials, 2020-2022
• Table 59 : Merck & Co. Inc.: Financials, 2020-2022
• Table 60 : Merck & Co. Inc.: Developments, 2020-2022
• Table 61 : NanoCarrier Co., Ltd.: Financials, 2020-2022
• Table 62 : NanoCarrier Co., Ltd.: Developments, 2020-2022
• Table 63 : Novartis AG: Financials, 2020-2022

List of Figures

• Summary Figure A : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Application, 2020-2028
• Summary Figure B : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Technology, 2020-2028
• Figure 1 : PESTEL Analysis: Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems Market
• Figure 2 : Global Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, 2020-2028
• Figure 3 : Global Market Shares for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Region, 2023
• Figure 4 : North American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 5 : North American Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 6 : European Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 7 : European Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 8 : Asia-Pacific Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 9 : Asia-Pacific Market Shares of Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, by Country, 2023
• Figure 10 : South American Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 11 : Middle Eastern and African Market for Nanoparticles in Biotechnology, Drug Development, and Drug Delivery Systems, 2020-2028
• Figure 12 : Bristol-Myers Squibb Co.: Research and Development Expenses, 2020-2022
• Figure 13 : Bristol-Myers Squibb Co.: Revenue Share, by Region, 2021
• Figure 14 : Camurus: Research and Development Expenses, 2020-2022
• Figure 15 : Camurus: Revenue Share, by Region, 2022
• Figure 16 : Camurus: SWOT Analysis
• Figure 17 : Gilead Sciences Inc.: Research and Development Expenses, 2020-2022
• Figure 18 : Gilead Sciences Inc.: Revenue Share, by Product Sales, 2022
• Figure 19 : GlaxoSmithKline PLC: Research and Development Expenses, 2020-2022
• Figure 20 : GlaxoSmithKline PLC: Revenue Share, by Segment, 2021
• Figure 21 : GlaxoSmithKline PLC: SWOT Analysis
• Figure 22 : Hoffman-La Roche Inc.: Research and Development Expenses, 2020-2022
• Figure 23 : Hoffman-La Roche Inc.: Revenue Share, by Segment, 2022
• Figure 24 : Merck & Co. Inc.: Research and Development Expenses, 2020-2022
• Figure 25 : Merck & Co. Inc.: Revenue Share, by Segment, 2022
• Figure 26 : Merck & Co. Inc.: SWOT Analysis
• Figure 27 : NanoCarrier Co., Ltd.: Net Assets, 2020-2022
• Figure 28 : Novartis AG: Operating Income, 2020-2022
• Figure 29 : Novartis AG: Revenue Share, by Segment, 2022
• Figure 30 : Novartis AG: SWOT Analysis